Therapeutic challenges in hepatitis C-infected injection drug using patients

Harm Reduction Journal

Volumn 3, Issue , 2006, Pages

  Cooper, Curtis L ^a,b   Mills, Edward J ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Centre for International Health and Human Rights Studies   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; SILYBUM MARIANUM EXTRACT; VIRUS RNA;

ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; CANNABIS ADDICTION; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DRUG ABUSE; DRUG ALCOHOL INTERACTION; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL HEALTH; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; REINFECTION; REVIEW; SOCIOECONOMICS; UNSPECIFIED SIDE EFFECT; VIOLENCE;

EID: 33845499896     PISSN: 14777517     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-3-31     Document Type: Review

References (86)

1. Remis RS: The prevalence of hepatitis in Canada. , Health Canada; 2003.
2. Heintges T, Wands JR: Hepatitis C virus: epidemiology and transmission. Hepatology 1997, 26:521-526.
3. Remis: Epidemiology of hepatitis C virus infection in Canada, 2002: March 27-31; Vancouver, B.C.. ; 2004.
4. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LF, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 2000, 284:450-456.
5. Stein MD, Charuvastra A, Anderson B, Sobota M, Friedmanna PD: Alcohol and HIV risk taking among intravenous drug users. Addict Behav 2002, 27:727-736.
6. Anderson BJ, Gogineni A, Charuvastra A, Longabaugh R, Stein MD: Adverse drinking consequences among alcohol abusing intravenous drug users. Alcohol Clin Exp Res 2001, 25:41-45.
7. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054-1058.
8. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34:809-816.
9. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995, 332:1463-1466.
10. Caly WR, Strauss E, Carrilho FJ, Laudanna AA: Different degrees of malnutrition and immunological alterations according to the aetiology of cirrhosis: a prospective and sequential study. Nutr J 2003, 2:10.
11. Lieber CS: Alcohol and the liver: 1994 update. Gastroenterology 1994, 106:1085-1105.
12. Muller MJ: Malnutrition in cirrhosis. J Hepatol 1995, 23 Suppl 1:31-35.
13. Smit E, Tang A: Nutritional assessment in intravenous drug users with HIV/AIDS. J Acquir Immune Defic Syndr 2000, 25 Suppl 1:562-9.
14. Kokkevi A, Stefanis C: Drug abuse and psychiatric comorbidity. Compr Psychiatry 1995, 36:329-337.
15. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ: Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000, 49:311-317.
16. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000, 157:867-876.
17. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117-123.
18. Balfour L, Cooper C, Kowal J, Tasca GA, Silverman AL, Kane M, Garber G: Depression and cigarette smoking independently contribute to reduced quality of life among Canadians living with hepatitis C. Can J Gastroenterol In press 2005.
19. Radloff LS: The CED-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurements 1977, 1:385-401.
20. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001, 105:45-55.
21. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO: Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85:498-502.
22. Mukaiya M, Nishi M, Miyake H, Hirata K: Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 1998, 45:2328-2332.
23. Duffy SA, Terrell JE, Valenstein M, Ronis DL, Copeland LA, Connors M: Effect of smoking, alcohol, and depression on the quality of life of head and neck cancer patients. Gen Hosp Psychiatry 2002, 24:140-147.
24. Haire-Joshu D, Heady S, Thomas L, Schechtman K, Fisher EB Jr.: Depressive symptomatology and smoking among persons with diabetes. Res Nurs Health 1994, 17:273-282.
25. Klein M, Cooper C: A randomized, placebo controlled trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy..
26. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A. Uebelhack R, Heinz A, van Boemmel F, Berg T: Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42:793-798.
27. O'Connor PG, Selwyn PA, Schottenfeld RS: Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994, 331:450-459.
28. Seeff LB, Hoofnagle JH: National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002, 36:S1-2.
29. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B: Is it Justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001, 345:211-214.
30. Braitstein P, Li K, Tyndall M, Spittal P, O'Shaughnessy MV, Schilder A, Johnston C, Hogg RS, Schechter MT: Sexual violence among a cohort of injection drug users. Soc Sci Med 2003, 57:561-569.
31. Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR: Non-adherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997, 102:164-170.
32. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP, Hwang JY, McCuttchan JA: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Aids 1999, 13:1099-1107.
33. Lucas GM, Cheever LW, Chaisson RE, Moore RD: Detrimental effects of continued illicit drug use on the treatment of HIV-I infection. J Acquir Immune Defic Syndr 2001, 27:251-259.
34. Sackett DL, SNow JC: The magnitude of compliance and non-compliance. In Compliance in Health Care Edited by: Haynes RB, Taylor DW and Sackett DL. Baltimore, Johns Hopkins University Press; 1979:11-22.
35. Miller NH: Compliance with treatment regimens in chronic asymptornatic diseases. Am J Med 1997, 102:43-49.
36. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH: Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000, 117:542-550.
37. Broers B, Morabia A, Hirschel B: A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994, 154:1121-1127.
38. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, Dewees-Dunk R, Levenson S, Kufe D, Craven DE: Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type I: a cross-sectional study in a municipal hospital clinic. Am J Med 1992, 92:495-502.
39. Mezzelani P, Venturini L, Turrina G, Lugoboni F, Des Jarlais DC: High compliance with a hepatitis B virus vaccination program among intravenous drug users. J Infect Dis 1991, 163:923.
40. Marco A, Cayla JA, Serra M, Pedro R, Sanrama C, Guerrero R, Ribot N: Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998, 12:967-971.
41. Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK: Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. J Urban Health 1999, 76:461-467.
42. Harrison K, Vlahov D, Jones K, Charron K, Clements ML: Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:386-390.
43. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188-193.
44. Sylvestre DL: Treatment of HCV in the methadone patient.: April 26-28; Chicago, Illinois. American Association for the Study of Liver Diseases; 2002:103-107.
45. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H: Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002, 8:45-49.
46. Edlin BR: Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002, 36:S210-9.
47. Burris S, Lurie P, Abrahamson D, Rich JD: Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Ann Intern Med 2000, 133:218-226.
48. Marsch LA: The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93:515-532.
49. Centres for Disease Control. Fact Sheet: physician prescription of sterile syringes to injection drug users[on-line]. Available:http:// www.cdc.gov/idu/facts/physician.htm). Academy of Educational Development.
50. Bhattacharya R, Shuhart MC: Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003, 36:242-252.
51. Tabone M, Sidoli L, Laudi C, Pellegrino S. Rocca G, Della Monica P, Fracchia M, Galatola G, Molinaro GC, Arico S, Pera A: Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Virol Hepat 2002, 9:288-294.
52. Ragni MV, Bontempo FA: Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999, 180:2027-2029.
53. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, Katayama K, Fusamoto H, Kamada T: Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994, 20:1115-1120.
54. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ: Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol 1996, 25:821-826.
55. Cooper C, Cameron DW: Effect of alcohol use on the impact of effective antiretroviral therapy for HIV co-infection on plasma HCV levels. Clin Infect Dis 2005, 41:S105-109.
56. Lucas GM, Gebo KA, Chaisson RE, Moore RD: Longitudinal assessment of the effects of drug and alcohol abuse on HIV-I treatment outcomes in an urban clinic. AIDS 2002, 16:767-774.
57. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B: Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998, 27:1717-1722.
58. Geissler M, Gesien A, Wands JR: Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997, 159:5107-5113.
59. Szabo G, Mandrekar P, Dolganiuc A, Catalano D, Kodys K: Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels. Alcohol Clin Exp Res 2001, 25:1766-1772.
60. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001, 120:512-524.
61. Emmen MJ, Schippers GM, Bleijenberg G, Wollersheim H: Effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting: systematic review. Bmj 2004, 328:318.
62. Winfried H, Zimmer C, Schiedermaier P, Grandt D: Biopschosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004, 66:954-958.
63. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, Rueff B, Valla DC, Degos F: Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001, 34:121-125.
64. Sladden TJ, Hickey AR, Dunn TM, Beard JR: Hepatitis C virus infection: impacts on behaviour and lifestyle. Aust N Z J Public Health 1998, 22:509-511.
65. Canadian tobacco use monitoring survey (CTUMS): prevalence 2000-2002. 2000.
66. Clarke JG, Stein MD, McGarry KA, Gogineni A: Interest in smoking cessation among injection drug users. Am J Addict 2001, 10:159-166.
67. Vogt MT, Hanscom B, Lauerman WC, Kang JD: Influence of smoking on the health status of spinal patients: the National Spine Network database. Spine 2002, 27:313-319.
68. Olufade AO, Shaw JW, Foster SA, Leischow SJ, Hays RD, Coons SJ: Development of the Smoking Cessation Quality of Life questionnaire. Clin Ther 1999, 21:2113-2130.
69. Wang CS, Wang ST, Chang TT, Yao WJ, Chou P: Smoking and alanine aminotransfererase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. Arch Intern Med 2002, 162:811-815.
70. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, Dhumeaux D: Impact of smoking on histological liver lesions In chronic hepatitis C. Gut 2003, 52:126-129.
71. Chong CA, Gulamhussein A, Heathcote EJ. Lilly L, Sherman M, Naglie G, Krahn M: Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98:630-638.
72. Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005:CD001292.
73. Fisher EB Jr., Haire-Joshu D, Morgan GD, Rehberg H, Rost K: Smoking and smoking cessation. Am Rev Respir Dis 1990, 142:702-720.
74. Hashibe M, Ford DE, Zhang ZF: Marijuana smoking and head and neck cancer. J Clin Pharmacol 2002, 42:103S-107S.
75. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999, 179:1254-1258.
76. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
77. Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006, 43:27-34.
78. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr., Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
79. Carrat F, Bani-Sadr F, Pol S, al.: Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV Infected Patients. Jama 2004, 292:2839-2848.
80. Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280-281.
81. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P: Mitochondrial toxic effects and ribavirin. Lancet 2001, 357:1803-1804.
82. Cooper CL, Al-Bedwawi S, Lee C, Garber G: Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006, 42:1674-1678.
83. Ter Riet G, Kleijnen J, Knipschild P: A meta-analysis of studies into the effect of acupuncture on addiction. Br J Gen Pract 1990, 40:379-382.
84. Mills EJ, Wu P, Gagnier J, Ebbert JO: Efficacy of acupuncture for cocaine dependence: a systematic review & meta-analysis. Harm Reduct J 2005, 2:4.
85. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K: Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005, 61:1-7.
86. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C: Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2005, 2